Novel biomarkers for sepsis are required because the existing inflammatory biomarkers for its diagnosis, such as C reactive protein (CRP), procalcitonin (PCT), and interleukin (IL)-6 (Enguix-Armada et al., 2016), have respective shortcomings in identification of sepsis onset. This evidence concerns the gene CRP and Sepsis.